Andrographis paniculata (Burm.f.) Nees — The "King of Bitters" of Ayurvedic and Chinese medicine, whose principal diterpene lactone andrographolide is one of the most potent naturally occurring NF-κB inhibitors identified — with antiviral, anti-inflammatory, immunostimulant, and hepatoprotective activity confirmed across multiple systematic reviews.
Andrographis paniculata is known across Asian medical systems as the "King of Bitters" — a title earned by its intensely bitter taste, derived from andrographolide, one of the most studied naturally occurring diterpenoid lactones in modern pharmacognosy. Its pharmacological profile is uniquely broad: antiviral, antibacterial, anti-inflammatory, hepatoprotective, immunostimulant, and anticancer activity all converge on andrographolide's master-switch inhibition of the NF-κB transcription pathway.
Andrographis paniculata occupies a central place in three major Asian medical traditions simultaneously: Ayurveda (India), Traditional Chinese Medicine, and Unani medicine. In Ayurveda it is classified as a Tikta (bitter) herb and is used for fevers, liver disorders, intestinal complaints, and infectious diseases — an application profile that has proven to be pharmacologically coherent with modern mechanistic understanding.
In folk medicine throughout South and Southeast Asia, andrographis was used for malaria, hepatitis, tuberculosis, snake venom, bacillary dysentery, bronchitis, colitis, and cough. In the Caribbean, where it naturalised after introduction, it was used as a depurative — a detoxifying agent reducing metabolic waste accumulation — as documented by the TRAMIL pharmacopoeial research programme.
The modern phytomedicine era for andrographis was largely catalysed by Scandinavian research in the 1990s, particularly work by Hancke and Burgos in Chile, who conducted the first rigorous double-blind placebo-controlled trials demonstrating efficacy for upper respiratory tract infections. The plant gained global attention during COVID-19 when India's Ministry of AYUSH included it in approved Ayurvedic formulations based on molecular docking models.
AYUSH COVID-19 Approval — 2020
India's Ministry of Ayurveda, Yoga and Naturopathy, Unani, Siddha and Homoeopathy (AYUSH) approved an Ayurvedic formulation containing Andrographis paniculata for COVID-19 management, based on molecular modelling studies showing binding affinity of andrographolide to SARS-CoV-2 spike protein and proteases. [10]
Traditional Systems
Ayurveda — India
Tikta (Bitter) · Hepatoprotective Herb
Used for fevers, jaundice, liver disorders, malaria, snake bites, dysentery. One of the most important Ayurvedic plants for infectious and hepatic disease.
Traditional Chinese Medicine
Chuān Xīn Lian · Clears Heat & Toxins
Classified as bitter, cold. Used to clear heat and resolve toxins, cool blood, reduce swelling. Indicated for respiratory infections, throat inflammation, dysentery, urinary infections.
Folk Medicine — Caribbean & SE Asia
TRAMIL Network · Depurative Use
Used as depurative (detoxification), antimalarial and antipyretic in naturalised Caribbean populations. TRAMIL pharmacopoeial research has documented and validated these traditional uses.
The molecule authority sites don't explain properly. Andrographolide is not just an anti-inflammatory — it is a master-switch inhibitor of NF-κB with unique covalent binding chemistry that sets it apart from all other plant-derived anti-inflammatory compounds.
Andrographolide is a bicyclic diterpenoid lactone — a structural class rarely found in medicinal plants. Its molecular formula is C₂₀H₃₀O₅ and molecular weight 350.45 g/mol. The molecule contains an α,β-unsaturated lactone moiety (the exocyclic alkene adjacent to the lactone carbonyl) that is directly responsible for its covalent modification of target proteins — including the p50 subunit of NF-κB. This electrophilic reactivity distinguishes andrographolide from non-covalent anti-inflammatory drugs and accounts for its unusually potent and sustained activity at low concentrations.
NF-κB (Nuclear Factor kappa-light-chain-enhancer of activated B cells) is the central transcription factor governing the expression of pro-inflammatory cytokines (TNF-α, IL-1β, IL-6, IL-8), adhesion molecules (ICAM-1, E-selectin), and anti-apoptotic proteins. It is activated in virtually every inflammatory, infectious, and oncological condition. Andrographolide blocks NF-κB by two mechanisms: (1) covalent modification of Cys62 on the p50 subunit, preventing DNA binding; and (2) stabilisation of IκBα by blocking its phosphorylation, preventing nuclear translocation of the p65/p50 complex. The result is suppression of the entire downstream inflammatory cascade from a single molecular intervention.
Andrographolide's primary pharmacological limitation is poor oral bioavailability — a challenge not adequately addressed by most supplement or health information sources. The compound has low water solubility, a slow dissolution rate, poor gastrointestinal absorption, rapid chemical and metabolic instability, and fast renal excretion. These four problems compound to severely limit the amount of andrographolide that reaches systemic circulation after oral dosing. A 2022 review (Loureiro Damasceno et al.) confirmed this and outlined pharmaceutical strategies to address it — including nanoparticle encapsulation, nanosuspensions, and nanoémulsions. [22][1]
Active pharmaceutical research is addressing the bioavailability problem through nanoformulation. A key finding: reducing andrographolide particle size from 49,461 nm (pure drug) to 255 nm (nanoparticle) increased oral bioavailability 2.2-fold. Lipid nanocarriers, PLGA nanoparticles, chitosan-based systems, and nanosuspensions are all under active investigation. Nanoformulations containing andrographolide have demonstrated superior anti-inflammatory and neuroprotective effects compared to equivalent doses of raw extract in animal models, suggesting clinical nanoformulations may dramatically improve therapeutic outcomes over current commercial preparations. [1][22]
2025 Supplement Quality Alert — Swiss Medical Weekly
Most commercial andrographis supplements contain less andrographolide than their labels claim.
A 2025 study published in Swiss Medical Weekly (Bourqui et al.) assessed the quality of Andrographis paniculata products sold internationally and found significant labelling inaccuracies and widespread under-dosing of andrographolides. This is pharmacologically critical — because andrographolide content is directly responsible for therapeutic activity, a product containing 30% less andrographolide than labelled delivers proportionally less clinical effect. [2]
Practical implication: When selecting an andrographis supplement, prioritise products with third-party verified andrographolide content (certificate of analysis from an independent laboratory). Products stating only "standardised to X% andrographolide" without third-party verification may not deliver the stated amount.
The aerial parts — stems, leaves, and inflorescences — harvested at peak andrographolide concentration (typically at flowering). Multiple galenical forms available.
Dry aerial parts of Andrographis paniculata — stems, leaves, and inflorescences. Harvested at the flowering stage when andrographolide content peaks. WHO monograph (Vol. 2) provides standardisation parameters. Andrographolide content typically 2–6% of dry weight.
Standardisation ranges from 4% to 31.3% andrographolide across commercial products. Higher standardisation ≠ better product if bioavailability is not addressed. A 2025 study found widespread label inaccuracies — always verify andrographolide content via third-party CoA. [2]
Dosages sourced from clinical trials and systematic reviews. Where available, expressed in andrographolide equivalents per the standardisation percentage of the preparation studied.
The aerial parts contain a rich ensemble of diterpenoid lactones, flavonoids, xanthones, and polysaccharides — though andrographolide dominates both commercial standardisation and pharmacological research.
Andrographolide and arabinogalactan both demonstrate direct antimicrobial activity. [3][4] Alcoholic leaf extract inhibits Escherichia coli and Staphylococcus aureus; methanolic extract inhibits Proteus vulgaris; aqueous extract inhibits HIV-1 in vitro. [5] Bactericidal activity also demonstrated against Salmonella, Shigella, and Mycobacterium species in multiple studies.
Documented antiviral activity against dengue virus, [6][7] influenza H1N1, [8] Herpes simplex virus, HIV, influenza A, hepatitis B (HBV), hepatitis C (HCV), HPV, and SARS-CoV-2. [9] Mechanisms include inhibition of viral replication, blockade of viral entry, and suppression of virus-induced NF-κB-dependent cytokine storms. One of the broadest antiviral spectra of any single phytochemical.
Andrographolide and arabinogalactan both stimulate innate and adaptive immunity. [11] Arabinogalactan activates macrophages through a mechanism parallel to echinacea's polysaccharide fraction. Andrographolide stimulates lymphocyte proliferation, enhances natural killer cell activity, and increases production of interferon-gamma and IL-2. The combined immunostimulant activity of both compound classes produces broader immune activation than either fraction alone.
Andrographolide and immunostimulant compounds from the plant demonstrate anticancer activity. [12][13] Mechanisms include NF-κB inhibition reducing anti-apoptotic protein expression, direct cytotoxic activity against cancer cell lines (colorectal, breast, lung, liver, prostate), cell cycle arrest at G1 and G2/M phases, inhibition of tumour angiogenesis, and suppression of metastatic adhesion via E-selectin blockade. A 2024 synthetic chemistry review catalogued pharmacomodulations of andrographolide for oncology applications.
NF-κB inhibition suppresses TNF-α, IL-1β, IL-6, IL-8, IL-17A, IFN-γ, COX-2, and iNOS expression — covering the principal mediators of both acute and chronic inflammation. Clinically validated in a double-blind RCT for knee osteoarthritis (ParActin® extract): significant reduction in pain and stiffness scores vs placebo over 12 weeks. [14] Antipyretic activity also documented in animal models. [15]
Andrographis species demonstrate in vitro and in vivo antidiabetic effects. [16] Andrographolide improves insulin sensitivity through AMPK pathway activation, reduces hepatic glucose output, and inhibits α-glucosidase — slowing glucose absorption from the intestine. Anti-inflammatory activity in pancreatic islets may also contribute to β-cell preservation. Preliminary data supports potential as an adjuvant in type 2 diabetes management.
Andrographolide protects liver cells against toxic injury. The classical study (Handa & Sharma, 1990) demonstrated protection against carbon tetrachloride-induced hepatotoxicity. [17] Mechanisms include antioxidant activity reducing hepatic oxidative stress, NF-κB suppression reducing inflammatory hepatocyte damage, and upregulation of Nrf2/HO-1 cytoprotective pathways. This hepatoprotective activity underpins the traditional Ayurvedic use for jaundice and liver disorders — an application now supported by modern mechanistic data.
Traditional use for dysentery, colitis, and diarrhoea is supported by preclinical data. Andrographolide inhibits intestinal secretion induced by enterotoxins and reduces intestinal motility in experimental models. Anti-inflammatory activity via NF-κB suppression in the intestinal epithelium is relevant to inflammatory bowel disease — clinical trials of HMPL-004 (standardised andrographis extract, 1,800 mg/day) in mild-to-moderate ulcerative colitis showed significant response vs placebo in phase 2 studies.
Traditional use as a malaria treatment (historically used as a quinine substitute) is supported by in vitro activity of andrographolide against Plasmodium falciparum. Antivenomous properties — protection against snake venom toxicity — were documented in traditional use and have partial in vitro corroboration. These properties contributed to andrographis' historical status as a general "antidote" in Ayurvedic and Caribbean folk medicine.
Andrographolide activates the Keap1/Nrf2/ARE/HO-1 pathway in hippocampal neurons, providing protection against oxidative and inflammatory neuronal damage. In Alzheimer's disease models, it reduces amyloid-beta₄₂-induced microglial activation and decreases IL-6, IL-1β, PGE₂, and nitric oxide production. Preliminary data from lipid nanocarrier studies shows alleviation of stress behaviours and hippocampal damage in neuroinflammatory mouse models. Clinical evidence is nascent but mechanistically compelling.
Whole-plant clinical indications organised by evidence strength, from systematic-review-validated to traditional and emerging applications.
Andrographolide operates through a small set of master regulatory pathways that each control large downstream biological effects — explaining why a single compound can produce such a broad activity profile.
Andrographolide's α,β-unsaturated lactone group covalently alkylates Cys62 on the p50 subunit of NF-κB, directly preventing the p50/p65 complex from binding DNA and activating transcription of pro-inflammatory genes. This covalent mechanism is irreversible for that particular protein molecule — producing more sustained inhibition than competitive inhibitors. Simultaneously, andrographolide blocks IκB kinase (IKK) activity, preventing IκBα phosphorylation and degradation — the upstream step that releases the p65/p50 dimer for nuclear translocation. Both mechanisms converge to fully block NF-κB pathway activation.
Andrographolide activates the Keap1/Nrf2/ARE/HO-1 antioxidant response pathway — the master regulator of cellular antioxidant defence. This activation upregulates heme oxygenase-1 (HO-1) and other antioxidant enzymes, providing protection against oxidative stress in the liver, neurons, and other tissues. Importantly, Nrf2 activation also suppresses NF-κB activity through a cross-pathway regulatory interaction — meaning andrographolide inhibits NF-κB through both direct (covalent) and indirect (Nrf2-mediated) mechanisms simultaneously. This dual mechanism underlies the hepatoprotective and neuroprotective properties.
Beyond NF-κB, andrographolide inhibits the MAPK signalling cascade (p38, ERK1/2, JNK phosphorylation) that feeds into pro-inflammatory cytokine production independently of NF-κB. It also modulates PI3K/Akt signalling — a pathway critical for cell survival, proliferation, and cancer cell resistance to apoptosis. Inhibition of Akt reduces anti-apoptotic protein expression (Bcl-2, Bcl-xL) and sensitises cancer cells to programmed death. This multi-pathway engagement explains the anticancer activity across multiple cancer cell line types.
Andrographolide's antiviral mechanism operates at multiple steps of the viral replication cycle: inhibition of viral attachment to host cells, blockade of viral protease enzymes required for polyprotein processing, and suppression of viral RNA replication. For SARS-CoV-2, molecular docking studies indicate binding affinity at the spike protein receptor-binding domain and the main protease (Mpro) — two validated antiviral drug targets. NF-κB inhibition additionally suppresses the cytokine storm response that causes the majority of COVID-19 severity, independent of direct antiviral effects.
A direct pharmacological comparison of two leading botanical immunomodulators with distinct mechanisms, evidence bases, and clinical applications.
The Bottom Line
For acute respiratory infections already underway, andrographis has stronger direct antiviral and anti-inflammatory evidence. For long-term immune prevention cycles, echinacea has more established evidence. Many integrative practitioners combine both — andrographis at symptom onset (short course, high dose), and echinacea in discontinuous 10–15 day monthly prevention cycles. Neither should be used continuously without medical supervision.
Generally well tolerated at standard doses. Fertility concerns in animal models are the most significant long-term safety signal. Pregnancy is an absolute contraindication.